ARTICLE | Clinical News

Pracinostat: Additional Phase II data

January 5, 2015 8:00 AM UTC

Data from 33 evaluable patients ages =65 with newly diagnosed AML who are unsuitable for intensive chemotherapy in a 2-stage, open-label, U.S. Phase II trial showed that 15 (45%) patients receiving 60 mg oral pracinostat given thrice weekly for 3 weeks of a 4-week cycle plus Vidaza azacitidine achieved the primary endpoint of a CR, CRi or MLFS. No patient who achieved a clinical response has progressed. Specifically, there were 9 CRs, 4 CRi’s and 2 patients with MLFS. Additionally, 3 patients achieved a partial response (PR) or a PR with incomplete blood count recovery and there were 4 cases of stable disease. The 60-day mortality rate is about 10%. Data were presented at the American Society of Hematology meeting in San Francisco. ...